NYSE
- USD
-
04/02/20
Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index
CI
04/02/20
Aevi Genomic Medicine, Inc. Announces Resignation of Directors
CI
03/02/20
Aevi Genomic Medicine, LLC(NasdaqCM:GNMX) dropped from NASDAQ Composite Index
CI
03/02/20
Cerecor Inc. completed the acquisition of Aevi Genomic Medicine, Inc..
CI
23/11/19
Aevi Genomic Medicine, Inc. Doses the First Patient with AEVI-002 in A Phase Ib Clinical Trial
CI
14/11/19
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
CI
14/11/19
Cerecor Inc. entered into a definitive merger agreement to acquire Aevi Genomic Medicine, Inc. for $15.6 million.
CI
14/08/19
Aevi Genomic Medicine, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
CI
07/08/19
Aevi Genomic Medicine, Inc. Obtains License for Medi2338, Phase 2-Ready Fully Human Monoclonal Antibody That Targets Interleukin 18 (IL-18)
CI
25/06/19
Declaration of Voting Results by Aevi Genomic Medicine, Inc.
CI
22/05/19
Aevi Genomic Medicine, Inc. Announces Executive Changes
CI
14/05/19
Aevi Genomic Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019
CI
30/03/19
The Children’s Hospital Nominates Board Candidate to Aevi Genomic
CI
04/02/20
AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
23/12/19
AEVI GENOMIC MEDICINE, INC. : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events (form 8-K)
AQ
11/12/19
AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A)
AQ
10/12/19
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
06/12/19
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company's product candidates include AEVI-001 and AEVI-002. The Company's research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). .
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-6pm CET
Select your edition
All financial news and data tailored to specific country editions
